Faculty of Medicine, Department of Radiology, Chulalongkorn University, Bangkok, Thailand.
Faculty of Medicine, Department of Surgery, Chulalongkorn University, Bangkok, Thailand.
Thorac Cancer. 2017 May;8(3):219-228. doi: 10.1111/1759-7714.12427. Epub 2017 Mar 21.
Locoregional failure is a major problem associated with chemoradiation treatment for squamous cell esophageal carcinoma. The aim of this study was to assess the feasibility, efficacy, and toxicity of preoperative radiation (dose > 50 Gy) with platinum-based chemotherapy followed by esophagectomy in locally advanced squamous cell carcinoma.
Data of patients with cT2-cT4 or node positive squamous cell carcinoma of the esophagus who received trimodality treatment between February 2006 and June 2015 were reviewed.
Forty-four patients were treated with intensity-modulated radiation therapy, volumetric-modulated arc therapy or three-dimensional radiation therapy. The median radiation dose was 60 Gy. The average volume of the lungs receiving 10 Gy was 48.1%, 20 Gy was 24.5%, and the average mean lung dose was 14 Gy. After chemoradiation, R0 resection was achieved in 31 patients (71%). Patients who received >60 Gy had a higher pathologic complete remission rate than those in the lower dose group (59.1% vs. 36.4%). R0 resection and radiation dose >60 Gy were associated with better overall survival in Cox proportional hazards regression analysis. The median follow-up duration was 22.4 months and median survival was 25.6 months. Two-year overall, progression-free survival and locoregional control rates were 55.9%, 28.6%, and 56%, respectively. The most common grade 3-4 toxicities were esophagitis (63.6%) and neutropenia (25%). Grade 3-4 postoperative morbidities included surgical wound infection (2.3%), acute renal failure (2.3%), and anastomosis stricture (2.3%).
Trimodality treatment with a high preoperative radiation dose and chemotherapy yielded a good pathologic complete response rate, and long-term survival with low toxicities.
局部区域复发是接受放化疗的鳞状细胞食管癌患者的主要问题。本研究旨在评估术前放疗(剂量>50Gy)联合铂类化疗后行根治性切除术治疗局部晚期食管鳞状细胞癌的可行性、疗效和毒性。
回顾性分析 2006 年 2 月至 2015 年 6 月接受新辅助放化疗的 cT2-cT4 或有淋巴结转移的食管鳞状细胞癌患者的临床资料。
44 例患者接受了调强放疗、容积调强弧形治疗或三维适形放疗。中位放疗剂量为 60Gy。肺 10Gy 体积、20Gy 体积和平均肺剂量分别为 48.1%、24.5%和 14Gy。放化疗后,31 例(71%)患者达到了 R0 切除。接受>60Gy 放疗的患者病理完全缓解率高于低剂量组(59.1% vs. 36.4%)。Cox 比例风险回归分析显示,R0 切除和放疗剂量>60Gy 与总生存时间延长有关。中位随访时间为 22.4 个月,中位总生存时间为 25.6 个月。2 年总生存率、无进展生存率和局部区域控制率分别为 55.9%、28.6%和 56%。最常见的 3-4 级毒性为食管炎(63.6%)和中性粒细胞减少症(25%)。3-4 级术后并发症包括手术切口感染(2.3%)、急性肾衰竭(2.3%)和吻合口狭窄(2.3%)。
高术前放疗剂量联合化疗的新辅助放化疗可获得较高的病理完全缓解率,并具有良好的长期生存和低毒性。